Literature DB >> 22156793

Future directions in palliative thoracic radiotherapy.

George Rodrigues1, Benjamin Movsas.   

Abstract

PURPOSE OF REVIEW: Recent systematic review, practice guidelines, and consensus statements have summarized the known clinical trial information with regards to the appropriate use of external-beam radiation, brachytherapy, and concurrent chemotherapy (with external-beam radiotherapy) in the palliation of chest symptoms with thoracic radiotherapy. The purpose of this review is to describe our present knowledge with regards to palliative thoracic radiotherapeutic maneuvers and to identify potential areas for future research inquiry consistent with current knowledge gaps. RECENT
FINDINGS: Two systematic reviews, one practice guideline, and one consensus statement based on published prospective clinical trials have demonstrated that palliative thoracic radiotherapy is an effective modality both in terms of symptom palliation and other important cancer outcomes. Evolving areas for future scientific inquiry include the role of advanced technologies such as intensity-modulated radiation therapy and image-guided radiation therapy, economic analyses as well as the creation of a common palliative endpoint that can be used for future clinical trials.
SUMMARY: Robust clinical trial information and high-level knowledge-translation documents currently exist to guide radiotherapy practitioners to provide standard-of-care treatment for thoracic palliative scenarios.

Entities:  

Mesh:

Year:  2012        PMID: 22156793     DOI: 10.1097/SPC.0b013e32834de6bd

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  2 in total

1.  Therapeutic effects of C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO-Me; bardoxolone methyl) on radiation-induced lung inflammation and fibrosis in mice.

Authors:  Yan-Yang Wang; Cui-Ying Zhang; Ya-Qiong Ma; Zhi-Xu He; Hong Zhe; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-06-22       Impact factor: 4.162

2.  PPM1A as a key target of the application of Jiawei‑Maxing‑Shigan decoction for the attenuation of radiation‑induced epithelial‑mesenchymal transition in type II alveolar epithelial cells.

Authors:  Jinhua Lu; Shengyou Lin; Zechen Lin; Xianlei Lin; Yuezhong Shen; Jingyang Su
Journal:  Mol Med Rep       Date:  2021-09-24       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.